Ken Garber. Show Affiliations »
Abstract
Mesh： See more » Antibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/therapeutic useAntineoplastic Agents/administration & dosageAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useDrug ApprovalHumansLymphoma, B-Cell/drug therapyMyelodysplastic Syndromes/chemically inducedRadiopharmaceuticals/administration & dosageRadiopharmaceuticals/adverse effectsRadiopharmaceuticals/therapeutic useRemission InductionUnited StatesUnited States Food and Drug Administration
Substances： See more » Antibodies, MonoclonalAntineoplastic AgentsRadiopharmaceuticalsibritumomab tiuxetantositumomab I-131
Year: 2003 PMID： 12569139 DOI： 10.1093/jnci/95.3.189
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506